Sonoma Pharmaceuticals, Inc. (SNOA) News
Filter SNOA News Items
SNOA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SNOA News Highlights
- SNOA's 30 day story count now stands at 2.
- Over the past 6 days, the trend for SNOA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- EYE, DLA and SKIN are the most mentioned tickers in articles about SNOA.
Latest SNOA News From Around the Web
Below are the latest news stories about SONOMA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate SNOA as an investment opportunity.
Sonoma Pharmaceuticals Announces Partnership with Daewoong Pharmaceutical for Distribution of Primocyn Skin Care in South KoreaSonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including dermatology, eye, oral and nasal care, and wound care, today announced that it has entered into a distribution agreement with Daewoong Pharmaceutical Co., Ltd. for the marketing and distribution of PrimocynTM Skin Solution products |
NEE Stock Alert: NextEra Energy Announces Leadership ChangesNextEra Energy (NEE) stock is on the move Wednesday after the Florida energy company announced changes to its leadership. |
NWSA Stock Alert: What to Know as Rupert Murdoch Abandons Merger PlansNews Corporation (NWSA) stock is in the news Wednesday after a merger plan between it and Fox Corporation (FOXA,FOX) was terminated. |
Why Is Sonoma Pharmaceuticals (SNOA) Up 70% Today?Sonoma Pharmaceuticals (SNOA) stock is rocketing higher on Wednesday following positive news for its Microcyn Rx products. |
Sonoma Pharmaceuticals and EMC Pharma Announce Department of Defense DAPA Registration for Microcyn(R) Rx ProductsSonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including dermatology, eye, oral and nasal care, and wound care, today announced that Microcyn® Rx products have received a Distribution and Pricing Agreement (DAPA) for distribution by the Defense Logistics Agency (DLA). |
Sonoma Pharmaceuticals Launches Two New Products Expanding Its Line of Office Dispense Products Exclusively for Dermatologists and Medical SpasSonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including dermatology, eye, oral and nasal care, and wound care today announced that it has launched a line of office dispense products exclusively for skin care professionals. |
Sonoma Pharmaceuticals Second Quarter 2023 Earnings: US$0.33 loss per share (vs US$0.043 loss in 2Q 2022)Sonoma Pharmaceuticals ( NASDAQ:SNOA ) Second Quarter 2023 Results Key Financial Results Revenue: US$3.33m (down 11... |
Sonoma Pharmaceuticals Reports Second Quarter 2023 Financial ResultsSonoma Pharmaceuticals, Inc. (Nasdaq:SNOA),a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care and dermatological conditions, today announced financial results for its second fiscal quarter and six months ended September 30, 2022. |
Sonoma Pharmaceuticals Launches Two New Dermatological Products for Over-The-Counter Use in the United StatesSonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care and dermatological conditions, today announced that it has launched Reliefacyn® Advanced Itch-Burn-Rash-Pain Relief Hydrogel and Rejuvacyn® Advanced Skin Repair Cooling Mist direct to consumers for |
Sonoma Pharmaceuticals to Exhibit at Upcoming CPHI Conference in Frankfurt, GermanySonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, and dermatological conditions, announced that it will be exhibiting at the CPHI Conference in Frankfurt, Germany on November 1-3, 2022. |